Skip to content

Video-assisted Hyperthermic Pleural Chemoperfusion vs Talc Pleurodesis for Refractory Malignant Pleural Effusions.

Video-assisted Hyperthermic Pleural Chemoperfusion Versus Bed-side Talc Slurry Pleurodesis for Refractory Malignant Pleural Effusions.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01409551
Enrollment
60
Registered
2011-08-04
Start date
2011-08-31
Completion date
2014-11-30
Last updated
2014-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cost Effectiveness, Efficacy of Intervention, Safety of Intervention

Keywords

Pleural effusion, VATS, hyperthermia, thoracostomy, pleurodesis

Brief summary

Aim of this study is to compare two methods of pleurodesis for refractory malignant pleural effusions, in terms of safety and efficacy.

Detailed description

The study compares prospectively two groups of patients with refractory maignant pleural effusion. Group A consists of patients undergoing video-assisted hyperthermic pleural chemoperfusion (with a pump machine) and group B includes patients undergoing bed-side tube thoracostomy and talc slurry pleurodesis.

Interventions

PROCEDUREVATS hyperthermic chemoperfusion

VATS, adhesiolysis, hyperthermic chemoperfusion (with a pump machine)

PROCEDUREBedside talc slurry pleurodesis

Bedside tube thoracostomy under local anesthesia. Bedside talc slurry pleurodesis.

Sponsors

Theagenio Cancer Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 75 Years
Healthy volunteers
No

Inclusion criteria

* Recurrent symptomatic malignant pleural effusion * No prior intrapleural therapy * Abscence of bronchial obstruction or fibrosis preventing lung reexpansion * No systemic chemotherapy immediately prior to or during the first 30-day interval following pleurodesis

Exclusion criteria

* Poor Karnofsky Performance Status

Design outcomes

Primary

MeasureTime frame
Recurrence of pleural effusion2 months following intervention

Secondary

MeasureTime frame
MorbidityPostoperative period (7 days following intervention)

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026